Relation of Serum Level of Lipocalin 2 to Her2/neu in Women with Breast Cancer

Authors

  • Atheer R. Atia1 , Salam S. Ahmed2

DOI:

https://doi.org/10.37506/ijfmt.v14i3.10805

Keywords:

Breast cancer, lipocalin 2, and Her2/neu

Abstract

Background: Breast cancer is the most common type of cancer worldwide, being one of the leading

causes morbidity in the female.(1) Lipocalin is a neutrophil gelatinase-associated lipocalin (NGAL) or

lipocalin 2 that is a 25 KDa glycoprotein, which was originally identified as a covalent complex with matrix

metalloproteinase-9 (MMP-9) in human neutrophil.(2) Lipocalin acts as bone-derived hormone which crosses

the blood brain barrier (BBB) and acts on the hypothalamus in the brain. The human epidermal growth

factor receptor 2 (HER-2/neu), has shown to have a prognostic value for the treatment with the monoclonal

antibody in breast cancer.(3)

Material and Method: This is a cross sectional, hospital based study. This study was carried out at the

Oncology Center in Kirkuk City-Iraq from the 1st of November 2018 to the end of June 2019. Forty-two

women with breast cancer were considered as a study group. Forty-four apparently healthy women without

breast cancer (relative of patients) and with a negative family history for the first and second degree relatives

of breast cancer were consider as a control group, their ages were from 23 to 70 year. By using a sterile

disposable syringe 10 mls of venous blood sample was drawn from each woman at morning and was kept in

a plain tube and allowed to clot at room temperature, then each sample was centrifuged at 6000 rpm to obtain

serum. Serum of the patients and controls had assay for lipocalin 2 and Her2/neu by ELISA.

Results: The mean serum level of lipocalin 2 was significantly elevated in breast cancer women compared

to control women (62.77 ± 6.1 and 23.98 ± 5.9 ng/l) respectively at a P value of 0.001. This study also

reveals that the mean serum level of Her2/neu was higher in breast cancer women (33.96 ± 2.7 ng/ml) as

compared with the control group (9.76 ± 1.6 ng/ml). This result was highly significant at a P value of 0.001.

This study found that there was a moderate positive correlation between lipocalin with Her2/neu in breast

cancer women (R: 0.33), which means that lipocalin 2 was proportionally elevated with increasing of Her2/

neu level.

Conclusion: This study reveals that there was a significant positive correlation between lipocalin and Her2/

neu in breast cancer women, the r value was 0.33.

Author Biography

Atheer R. Atia1 , Salam S. Ahmed2

1 Asst. Lec. Kirkuk General Hospital, Kirkuk Governorate/Iraq, 2Prof Dr. Professor of Clinical & Medical

Biochemistry–A General Pediatrician, College of Medicine–University of Tikrit/Iraq

Published

2020-07-30

How to Cite

Atheer R. Atia1 , Salam S. Ahmed2. (2020). Relation of Serum Level of Lipocalin 2 to Her2/neu in Women with Breast Cancer. Indian Journal of Forensic Medicine & Toxicology, 14(3), 2456-2462. https://doi.org/10.37506/ijfmt.v14i3.10805

Issue

Vol. 14 No. 3 (2020): Indian Journal of Forensic Medicine & Toxicology

Section

Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details

https://creativecommons.org/licenses/

CC BY

This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.

  1. The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
  1. The journal allows the author(s) to hold the copyright without restrictions.
  1. The journal allows the author(s) to retain publishing rights without restrictions